Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T37847
(Former ID: TTDS00310)
|
|||||
| Target Name |
Herpes simplex virus DNA polymerase UL30 (HSV UL30)
|
|||||
| Synonyms |
HSV DNA polymerase catalytic subunit
Click to Show/Hide
|
|||||
| Gene Name |
HSV UL30
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 6 Target-related Diseases | + | ||||
| 1 | Cytomegaloviral disease [ICD-11: 1D82] | |||||
| 2 | Herpes simplex infection [ICD-11: 1F00] | |||||
| 3 | Human immunodeficiency virus disease [ICD-11: 1C60-1C62] | |||||
| 4 | Mature B-cell lymphoma [ICD-11: 2A85] | |||||
| 5 | Retinal inflammation [ICD-11: 9B72] | |||||
| 6 | Virus infection [ICD-11: 1A24-1D9Z] | |||||
| Function |
Replicates viral genomic DNA. The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA-binding protein. Additionally, the polymerase contains an intrinsic ribonuclease H (RNase H) activity that specifically degrades RNA/DNA heteroduplexes or duplex DNA substrates in the 5' to 3' direction. Therefore, it can catalyze the excision of the RNA primers that initiate the synthesis of Okazaki fragments at a replication fork during viral DNA replication.
Click to Show/Hide
|
|||||
| BioChemical Class |
DNA polymerase type-B
|
|||||
| UniProt ID | ||||||
| Sequence |
MFSGGGGPLSPGGKSAARAASGFFAPAGPRGASRGPPPCLRQNFYNPYLAPVGTQQKPTG
PTQRHTYYSECDEFRFIAPRVLDEDAPPEKRAGVHDGHLKRAPKVYCGGDERDVLRVGSG GFWPRRSRLWGGVDHAPAGFNPTVTVFHVYDILENVEHAYGMRAAQFHARFMDAITPTGT VITLLGLTPEGHRVAVHVYGTRQYFYMNKEEVDRHLQCRAPRDLCERMAAALRESPGASF RGISADHFEAEVVERTDVYYYETRPALFYRVYVRSGRVLSYLCDNFCPAIKKYEGGVDAT TRFILDNPGFVTFGWYRLKPGRNNTLAQPAAPMAFGTSSDVEFNCTADNLAIEGGMSDLP AYKLMCFDIECKAGGEDELAFPVAGHPEDLVIQISCLLYDLSTTALEHVLLFSLGSCDLP ESHLNELAARGLPTPVVLEFDSEFEMLLAFMTLVKQYGPEFVTGYNIINFDWPFLLAKLT DIYKVPLDGYGRMNGRGVFRVWDIGQSHFQKRSKIKVNGMVNIDMYGIITDKIKLSSYKL NAVAEAVLKDKKKDLSYRDIPAYYAAGPAQRGVIGEYCIQDSLLVGQLFFKFLPHLELSA VARLAGINITRTIYDGQQIRVFTCLLRLADQKGFILPDTQGRFRGAGGEAPKRPAAARED EERPEEEGEDEDEREEGGGEREPEGARETAGRHVGYQGARVLDPTSGFHVNPVVVFDFAS LYPSIIQAHNLCFSTLSLRADAVAHLEAGKDYLEIEVGGRRLFFVKAHVRESLLSILLRD WLAMRKQIRSRIPQSSPEEAVLLDKQQAAIKVVCNSVYGFTGVQHGLLPCLHVAATVTTI GREMLLATREYVHARWAAFEQLLADFPEAADMRAPGPYSMRIIYGDTDSIFVLCRGLTAA GLTAVGDKMASHISRALFLPPIKLECEKTFTKLLLIAKKKYIGVIYGGKMLIKGVDLVRK NNCAFINRTSRALVDLLFYDDTVSGAAAALAERPAEEWLARPLPEGLQAFGAVLVDAHRR ITDPERDIQDFVLTAELSRHPRAYTNKRLAHLTVYYKLMARRAQVPSIKDRIPYVIVAQT REVEETVARLAALRELDAAAPGDEPAPPAALPSPAKRPRETPSPADPPGGASKPRKLLVS ELAEDPAYAIAHGVALNTDYYFSHLLGAACVTFKALFGNNAKITESLLKRFIPEVWHPPD DVAARLRTAGFGAVGAGATAEETRRMLHRAFDTLA Click to Show/Hide
|
|||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 8 Approved Drugs | + | ||||
| 1 | Aciclovir | Drug Info | Approved | Virus infection | [4], [5] | |
| 2 | Cidofovir | Drug Info | Approved | Cytomegalovirus infection | [6] | |
| 3 | Cytarabine | Drug Info | Approved | Acute lymphoblastic leukaemia | [7], [8], [9] | |
| 4 | Foscavir | Drug Info | Approved | Cytomegalovirus retinitis | [10] | |
| 5 | Ganciclovir | Drug Info | Approved | Virus infection | [2] | |
| 6 | Valaciclovir | Drug Info | Approved | Virus infection | [11], [2] | |
| 7 | Valacyclovir Hydrochloride | Drug Info | Approved | Herpes simplex virus infection | [3] | |
| 8 | Valganciclovir | Drug Info | Approved | Virus infection | [12], [2] | |
| Clinical Trial Drug(s) | [+] 6 Clinical Trial Drugs | + | ||||
| 1 | Netivudine | Drug Info | Phase 3 | Virus infection | [13] | |
| 2 | Fialuridine | Drug Info | Phase 2 | Hepatitis B virus infection | [14] | |
| 3 | URSOLIC ACID | Drug Info | Phase 2 | Metabolic syndrome x | [15] | |
| 4 | Valomaciclovir stearate | Drug Info | Phase 2 | Varicella zoster virus infection | [16] | |
| 5 | GS-9219 | Drug Info | Phase 1/2 | Solid tumour/cancer | [17] | |
| 6 | BETULINIC ACID | Drug Info | Phase 1 | Melanoma | [19] | |
| Discontinued Drug(s) | [+] 3 Discontinued Drugs | + | ||||
| 1 | CHPMPC | Drug Info | Discontinued in Phase 1 | Virus infection | [21] | |
| 2 | Amitivir | Drug Info | Terminated | Virus infection | [23] | |
| 3 | GR-95168 | Drug Info | Terminated | Virus infection | [24] | |
| Preclinical Drug(s) | [+] 1 Preclinical Drugs | + | ||||
| 1 | IDX136 | Drug Info | Preclinical | Hepatitis C virus infection | [22] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Modulator | [+] 9 Modulator drugs | + | ||||
| 1 | Aciclovir | Drug Info | [25] | |||
| 2 | Cidofovir | Drug Info | [25] | |||
| 3 | Valacyclovir Hydrochloride | Drug Info | [25] | |||
| 4 | Netivudine | Drug Info | [30] | |||
| 5 | Fialuridine | Drug Info | [31] | |||
| 6 | Valomaciclovir stearate | Drug Info | [33] | |||
| 7 | CHPMPC | Drug Info | [39] | |||
| 8 | Amitivir | Drug Info | [42] | |||
| 9 | GR-95168 | Drug Info | [43] | |||
| Inhibitor | [+] 34 Inhibitor drugs | + | ||||
| 1 | Cytarabine | Drug Info | [26] | |||
| 2 | Foscavir | Drug Info | [27] | |||
| 3 | Ganciclovir | Drug Info | [28] | |||
| 4 | Valaciclovir | Drug Info | [29] | |||
| 5 | Valganciclovir | Drug Info | [27] | |||
| 6 | URSOLIC ACID | Drug Info | [32] | |||
| 7 | GS-9219 | Drug Info | [34] | |||
| 8 | BETULINIC ACID | Drug Info | [35] | |||
| 9 | Guanosine | Drug Info | [36] | |||
| 10 | Aphidicolin | Drug Info | [37], [38] | |||
| 11 | IDX136 | Drug Info | [40], [41] | |||
| 12 | (+)-Myristinin A | Drug Info | [44] | |||
| 13 | (24E)-3beta-hydroxy-7,24-euphadien-26-oic acid | Drug Info | [45] | |||
| 14 | 2'-deoxythymidine triphosphate | Drug Info | [46] | |||
| 15 | 3-cis-p-coumaroyl maslinic acid | Drug Info | [35] | |||
| 16 | 3-Oximo-olean-12-en-29-oic acid | Drug Info | [47] | |||
| 17 | 3alpha-O-trans-p-coumaroyl-7-labden-15-oic acid | Drug Info | [48] | |||
| 18 | 3beta-hydroxyrus-18,20(30)-dien-28-oic acid | Drug Info | [32] | |||
| 19 | 5-propenyl-2'-deoxyuridine triphosphate | Drug Info | [46] | |||
| 20 | 5-propenyl-arabinofuranosyluracil 5'-triphosphate | Drug Info | [46] | |||
| 21 | 6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione | Drug Info | [49] | |||
| 22 | 6-(4-Bromo-phenylamino)-1H-pyrimidine-2,4-dione | Drug Info | [49] | |||
| 23 | 6-(4-Chloro-phenylamino)-1H-pyrimidine-2,4-dione | Drug Info | [49] | |||
| 24 | Alpha,beta-methylene-dATP | Drug Info | [50] | |||
| 25 | Alpha,beta-methylene-dCTP | Drug Info | [50] | |||
| 26 | Alpha,beta-methylene-dTTP | Drug Info | [50] | |||
| 27 | DdCTP SODIUM | Drug Info | [51] | |||
| 28 | Gallic acid 5,6-dihydroxy-3-carboxyphenylester | Drug Info | [52] | |||
| 29 | Guanosine-5'-Monophosphate | Drug Info | [36] | |||
| 30 | Mahureone D | Drug Info | [51] | |||
| 31 | OLEANOLIC_ACID | Drug Info | [32] | |||
| 32 | PENICILLIOL A | Drug Info | [53] | |||
| 33 | PMEA | Drug Info | [54] | |||
| 34 | TALAROFLAVONE | Drug Info | [55] | |||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: N-(4-chlorobenzyl)-1-methyl-6-(morpholinomethyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide | Ligand Info | |||||
| Structure Description | HSV1 polymerase ternary complex with dsDNA and PNU-183792 | PDB:7LUF | ||||
| Method | X-ray diffraction | Resolution | 3.50 Å | Mutation | No | [56] |
| PDB Sequence |
TGPTQRHTYY
68 SECDEFRFIA78 PRVLDEDAPP88 EKRAGVHDGH98 LKRAPKVYCG108 GDERDVLRVG 118 SGGFWPRRSR128 LWGGVDHAPA138 GFNPTVTVFH148 VYDILENVEH158 AYGMRAAQFH 168 ARFMDAITPT178 GTVITLLGLT188 PEGHRVAVHV198 YGTRQYFYMN208 KEEVDRHLQC 218 RAPRDLCERM228 AAALRESPGA238 SFRGISADHF248 EAEVVERTDV258 YYYETRPALF 268 YRVYVRSGRV278 LSYLCDNFCP288 AIKKYEGGVD298 ATTRFILDNP308 GFVTFGWYRL 318 KPGRNNTLAQ328 PRAPMAFGTS338 SDVEFNCTAD348 NLAIEGGMSD358 LPAYKLMCFD 368 IACKAGGEDE378 LAFPVAGHPE388 DLVIQISCLL398 YDLSTTALEH408 VLLFSLGSCD 418 LPESHLNELA428 ARGLPTPVVL438 EFDSEFEMLL448 AFMTLVKQYG458 PEFVTGYNII 468 NFDWPFLLAK478 LTDIYKVPLD488 GYGRMNGRGV498 FRVWDIGQSH508 FQKRSKIKVN 518 GMVNIDMYGI528 ITDKIKLSSY538 KLNAVAEAVL548 KDKKKDLSYR558 DIPAYYAAGP 568 AQRGVIGEYC578 IQDSLLVGQL588 FFKFLPHLEL598 SAVARLAGIN608 ITRTIYDGQQ 618 IRVFTCLLRL628 ADQKGFILPD638 TQVGYQGARV701 HDPTSGFHVN711 PVVGFDFASL 721 YPSIIQAHNL731 CFSTLSLRAD741 AVAHLEAGKD751 YLEIEVGGRR761 LFFVKAHVRE 771 SLLSILLRDW781 LAMRKQIRSR791 IPQSSPEEAV801 LLDKQQAAIK811 VVCNSVYGFT 821 GVQHGLLPCL831 HVAATVTTIG841 REMLLATREY851 VHARWAAFEQ861 LLADFPEAAD 871 MRAPGPYSMR881 IIYGDTDSIF891 VLCRGLTAAG901 LTAMGDKMAS911 HISRALFLPP 921 IKLECEKTFT931 KLLLIAKKKY941 IGVIYGGKML951 IKGVDLVRKN961 NCAFINRTSR 971 ALVDLLFYDD981 TVSGAAAALA991 ERPAEEWLAR1001 PLPEGLQAFG1011 AVLVDAHRRI 1021 TDPERDIQDF1031 VLTAELSRHP1041 RAYTNKRLAH1051 LTVYYKLMAR1061 RAQVPSIKDR 1071 IPYVIVAQTR1081 EVEETVARLA1091 ALRELVSELA1143 EDPAYAIAHG1153 VALNTDYYFS 1163 HLLGAACVTF1173 KALFGNNAKI1183 TESLLKRFIP1193 EVWH
|
|||||
|
|
||||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Similarity Proteins
|
|
|
There is no similarity protein (E value < 0.005) for this target
|
| Chemical Structure based Activity Landscape of Target | Top |
|---|---|
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. Drugs. 2009;69(2):151-66. | |||||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4829). | |||||
| REF 5 | Drug information of Aciclovir, 2008. eduDrugs. | |||||
| REF 6 | Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416. | |||||
| REF 7 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4827). | |||||
| REF 8 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071471. | |||||
| REF 9 | Incorporation of gemcitabine and cytarabine into DNA by DNA polymerase beta and ligase III/XRCC1. Biochemistry. 2010 Jun 15;49(23):4833-40. | |||||
| REF 10 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020068. | |||||
| REF 11 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4824). | |||||
| REF 12 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4716). | |||||
| REF 13 | ClinicalTrials.gov (NCT00002315) A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems. U.S. National Institutes of Health. | |||||
| REF 14 | ClinicalTrials.gov (NCT00000654) The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU. U.S. National Institutes of Health. | |||||
| REF 15 | ClinicalTrials.gov (NCT02337933) Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome. U.S. National Institutes of Health. | |||||
| REF 16 | ClinicalTrials.gov (NCT00831103) A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster. U.S. National Institutes of Health. | |||||
| REF 17 | ClinicalTrials.gov (NCT00499239) A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). U.S. National Institutes of Health. | |||||
| REF 18 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001059) | |||||
| REF 19 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3945). | |||||
| REF 20 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012718) | |||||
| REF 21 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004825) | |||||
| REF 22 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800042373) | |||||
| REF 23 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001039) | |||||
| REF 24 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003388) | |||||
| REF 25 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
| REF 26 | Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72. | |||||
| REF 27 | Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22. | |||||
| REF 28 | Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2009 Feb;30(2):77-81. | |||||
| REF 29 | Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient. Oral Microbiol Immunol. 2009 Apr;24(2):109-15. | |||||
| REF 30 | Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs. 1999 Feb;57(2):187-206. | |||||
| REF 31 | Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3592-7. | |||||
| REF 32 | DNA polymerase beta inhibitors from Baeckea gunniana. J Nat Prod. 1999 Dec;62(12):1624-6. | |||||
| REF 33 | Progress in the Development of New Therapies for Herpesvirus Infections. Curr Opin Virol. 2011 December 1; 1(6): 548-554. | |||||
| REF 34 | GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin Cancer Res. 2008 May 1;14(9):2824-32. | |||||
| REF 35 | DNA polymerase beta inhibitors from Tetracera boiviniana. J Nat Prod. 1999 Dec;62(12):1660-3. | |||||
| REF 36 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||||
| REF 37 | Proteasome regulation of ULBP1 transcription. J Immunol. 2009 May 15;182(10):6600-9. | |||||
| REF 38 | Characterization of an aphidicolin-resistant mutant of herpes simplex virus type 2 which induces an altered viral DNA polymerase. Virology. 1984 May;135(1):87-96. | |||||
| REF 39 | Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase.. Antimicrob Agents Chemother. 1997 March; 41(3): 641-646. | |||||
| REF 40 | Therapy with amineptine, a dopamine reuptake inhibitor, in patients with major depression. Indian J Psychiatry. 1997 Apr;39(2):147-53. | |||||
| REF 41 | Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic. News for Idenix. 2008. | |||||
| REF 42 | Approaches and strategies for the treatment of influenza virus infections. Antivir Chem Chemother. 1999 Jul;10(4):155-85. | |||||
| REF 43 | US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes. | |||||
| REF 44 | (+)-Myristinins A and D from Knema elegans, which inhibit DNA polymerase beta and cleave DNA. J Nat Prod. 2005 Nov;68(11):1625-8. | |||||
| REF 45 | A new 7,8-euphadien-type triterpenoid from Brackenridgea nitida and Bleasdalea bleasdalei that inhibits DNA polymerase beta. J Nat Prod. 2000 Oct;63(10):1356-60. | |||||
| REF 46 | Inhibition of human hepatitis B virus DNA polymerase and duck hepatitis B virus DNA polymerase by triphosphates of thymidine analogs and pharmacokinetic properties of the corresponding nucleosides. JMed Virol. 1988 Dec;26(4):353-62. | |||||
| REF 47 | DNA polymerase beta inhibitors from Sandoricum koetjape. J Nat Prod. 1999 Aug;62(8):1110-3. | |||||
| REF 48 | Harbinatic acid, a novel and potent DNA polymerase beta inhibitor from Hardwickia binata. J Nat Prod. 1999 Jul;62(7):1000-2. | |||||
| REF 49 | Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8. | |||||
| REF 50 | Alpha,beta-methylene-2'-deoxynucleoside 5'-triphosphates as noncleavable substrates for DNA polymerases: isolation, characterization, and stability... J Med Chem. 2008 Oct 23;51(20):6460-70. | |||||
| REF 51 | Acylphloroglucinol derivatives from Mahurea palustris. J Nat Prod. 2005 Jul;68(7):979-84. | |||||
| REF 52 | Differential inhibition of reverse transcriptase and various DNA polymerases by digallic acid and its derivatives. J Nat Prod. 1990 Sep-Oct;53(5):1234-40. | |||||
| REF 53 | Penicilliols A and B, novel inhibitors specific to mammalian Y-family DNA polymerases. Bioorg Med Chem. 2009 Mar 1;17(5):1811-6. | |||||
| REF 54 | Herpes simplex virus-specified DNA polymerase is the target for the antiviral action of 9-(2-phosphonylmethoxyethyl)adenine. J Biol Chem. 1991 Jan 5;266(1):238-44. | |||||
| REF 55 | 1-deoxyrubralactone, a novel specific inhibitor of families X and Y of eukaryotic DNA polymerases from a fungal strain derived from sea algae. Bioorg Med Chem. 2008 Mar 15;16(6):2939-44. | |||||
| REF 56 | Structural understanding of non-nucleoside inhibition in an elongating herpesvirus polymerase. Nat Commun. 2021 May 24;12(1):3040. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.